Fluorescent gold nanoclusters (FANC) are 2 nm-diameter nanoparticles with dihydroilpoiate coating. In addition to the antioxidant effects of FANC, we had identified the anti-inflammatory ability of FANC in human aortic endothelial cells and mice (Patent # I74250). In apoprotein E deficient (ApoE‑/‑) mice fed Western diet, daily oral intake of 300 nM FANC is effective to lower the blood total cholesterol and LDL-C level, as well as to attenuate the aortic atheroma burden. The acute, subacute and chronic toxicity test also showed no detectable damage of tissues and organs in male ICR mice. The no observed adverse effect level (NOAEL) at chronic toxicity test was 20 M/100 L/25 g FANC daily. Therefore, FANC can be developed as a health supplement and drug.
Features / strengths
FANC are different from classical organic synthesized lipid lowering drugs and are not accumulated and metabolized in liver, suggesting without hepatic toxicity. We conducted one year of animal study showed that FANC do not cause infertility, embryo abnormality and no accumulation in vital organs. Importantly, the cost of FANC in therapy is reasonable. FANC markedly reduced atherosclerosis and cholesterol in 8-week animal tests, showing the marketing potential. Commercialization of FANC will be a novel drug for cardiovascular disease, benefit to patients worldwide and contribute to the development of bio- and nanotechnology of our country.
Specification in detail